AGP Picks
View all

Piraeus Medical launches 35 Helix neurovascular guidewire in the U.S.

4 hours ago
By AI, Created 22:28 UTC, Nov 18, 2026, AGP -

Piraeus Medical has launched its 35 Helix Neurovascular Guidewire in the United States after FDA clearance, and the first U.S. cases are complete. The company says the 0.035-inch wire is designed to reduce contact area and expand options in neurointerventional access.

Why it matters: - The 35 Helix Guidewire gives neurointerventional physicians another U.S.-available access tool after FDA clearance. - Piraeus Medical says the 0.035-inch wire is built to reduce contact area by 58% versus competitive 0.035-inch wires, which could affect trackability and device delivery in complex cases. - The launch expands Piraeus Medical's neurointerventional access portfolio, which already includes the 6F 70 NeuGlide, 7F 87 NeuGlide+ and 8F 93 NeuFlex catheters.

What happened: - Piraeus Medical announced the U.S. launch of the 35 Helix Neurovascular Guidewire on Nov. 18, 2026, after FDA clearance. - The company said the first 35 Helix guidewire cases have been completed in the U.S. - The product is built on Piraeus Medical's patent pending Helix construction.

The details: - The 35 Helix Guidewire is a 0.035-inch neurovascular guidewire intended for general vascular use by physicians to introduce and position catheters or other interventional devices within the neuro and peripheral vasculatures. - The guidewire is not intended for use in the coronary vasculature. - Product labeling includes indications, contraindications, warnings and instructions for use. - Piraeus Medical says the design uses patent pending Helix construction to reduce contact area compared with competitive 0.035-inch wires. - The company directs clinicians to more information and safety details.

Between the lines: - The launch signals Piraeus Medical is pushing deeper into neurovascular access rather than relying only on catheters. - A successful first case using a single wire without exchanges suggests the company wants the 35 Helix positioned as a workflow-improving tool for difficult thrombectomy cases. - The quoted case result from LSU Neurosurgery is a clinical example, not a broad performance claim across all patients.

What's next: - Piraeus Medical is likely to use early U.S. case experience to support broader clinical adoption of the 35 Helix Guidewire. - The company is also continuing to market its other neurointerventional access products alongside the new wire. - Healthcare professionals can contact Piraeus Medical Customer Service at +1 507-782-0184 for product information.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

North America Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

North America Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.